Last updated July 4, 2026
Key finding
Body weight reduction of ≥15% with tirzepatide.
This study investigated factors associated with body weight reduction in adults with Type 2 diabetes using tirzepatide, finding that higher doses led to greater weight loss.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated factors associated with body weight reduction in adults with Type 2 diabetes using tirzepatide, finding that higher doses led to greater weight loss.
These findings are significant for clinicians treating patients with Type 2 diabetes, as effective weight management can lead to better overall health outcomes. Understanding the dose-response relationship of tirzepatide can help tailor treatments to individual patient needs, potentially improving adherence and long-term success.
The study's effectiveness results were unclear due to unspecified p-values. Limited generalizability due to the specific population studied. Potential unmeasured confounders affecting outcomes.
Published in
Publication details and source links for this paper.
Maciej TM, Rachel LB, Naveed S, et al. Factors Associated with Body Weight Reduction with Tirzepatide in Adults with Type 2 Diabetes. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135
Body weight reduction of ≥15% was significantly associated with higher tirzepatide doses.
Greater reductions in HbA1c were observed with higher categorical weight reductions.
Higher categorical weight reductions led to significant decreases in triglycerides.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Tirzepatide and Blood pressure reduction, Body weight, HbA1c, and 2 more.
This study contributes evidence to
Primary intervention
Tirzepatide
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
5
Evidence pairs
730
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence relationship
Save evidence
Core evidence
The primary outcomes reported in this study.
Tirzepatide → Blood pressure reduction
Tirzepatide → Blood pressure reduction
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and HbA1c, GLP-1 Receptor Agonists and Body Weight.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
Jump to pre-filtered views in Evidence Explorer.
13 results
12 results
13 results
13 results
12 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists appears to improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 83.4 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 32 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Body weight
EvidenceScore™ Strong | EvidenceScore™ 82.7 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 33 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Triglycerides
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
GLP-1 Receptor Agonists may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Blood pressure reduction
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
